ATE416754T1 - Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff - Google Patents

Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff

Info

Publication number
ATE416754T1
ATE416754T1 AT04740892T AT04740892T ATE416754T1 AT E416754 T1 ATE416754 T1 AT E416754T1 AT 04740892 T AT04740892 T AT 04740892T AT 04740892 T AT04740892 T AT 04740892T AT E416754 T1 ATE416754 T1 AT E416754T1
Authority
AT
Austria
Prior art keywords
chemolockist
polyacrylate
mucoadhesive composition
composition
mucoadhesive
Prior art date
Application number
AT04740892T
Other languages
English (en)
Inventor
Pascale Hubert
Brigitte Evrard
Luc Delattre
Jacques Boniver
Philippe Delvenne
Agnes Noel
Francis Frankenne
Jean-Michel Foidart
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Application granted granted Critical
Publication of ATE416754T1 publication Critical patent/ATE416754T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04740892T 2003-07-31 2004-07-09 Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff ATE416754T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317999.1A GB0317999D0 (en) 2003-07-31 2003-07-31 Improvements in or relating to drug delivery systems

Publications (1)

Publication Number Publication Date
ATE416754T1 true ATE416754T1 (de) 2008-12-15

Family

ID=27799593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04740892T ATE416754T1 (de) 2003-07-31 2004-07-09 Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff

Country Status (8)

Country Link
US (1) US20060228417A1 (de)
EP (1) EP1658046B1 (de)
JP (1) JP2007500673A (de)
AT (1) ATE416754T1 (de)
AU (1) AU2004262873A1 (de)
DE (1) DE602004018326D1 (de)
GB (1) GB0317999D0 (de)
WO (1) WO2005013933A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674077A1 (de) * 2004-12-27 2006-06-28 Université de Liège Mucoadhasive Formulierungen enthaltend Chemokine
WO2006084131A2 (en) * 2005-02-01 2006-08-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection
WO2007065128A2 (en) * 2005-11-30 2007-06-07 Auburn University Human alpha-defensins inhibit interleukin-1beta release
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
EP2370112B1 (de) 2008-11-24 2017-04-05 Bonus Cellora Ltd. Implantierbare matrixzusammensetzung mit eingebetteten liposomen, und ihre verwendung
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
CN107648668B (zh) 2010-10-06 2021-06-18 哈佛学院董事会 用于基于材料的细胞疗法的可注射的成孔水凝胶
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
EP2714073B1 (de) 2011-06-03 2021-03-10 President and Fellows of Harvard College Krebsimpfstoff zur in-situ-antigen-erzeugung
DK2838515T3 (da) 2012-04-16 2020-02-24 Harvard College Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
CN109260465A (zh) 2012-11-14 2019-01-25 史密夫和内修公司 稳定的嗜热菌蛋白酶水凝胶
RU2015137174A (ru) 2013-03-15 2017-04-24 Смит энд Невью, Инк. Растворимая образующая гель плёнка и способ очистки раны
EP3137105A4 (de) 2014-04-30 2017-12-27 President and Fellows of Harvard College Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
TW201808987A (zh) 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
WO2020002650A1 (en) * 2018-06-29 2020-01-02 Targovax Asa A formulation
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
DE69739583D1 (de) * 1996-11-14 2009-10-29 Lipomedica Ehf Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders

Also Published As

Publication number Publication date
EP1658046B1 (de) 2008-12-10
US20060228417A1 (en) 2006-10-12
WO2005013933A1 (en) 2005-02-17
DE602004018326D1 (de) 2009-01-22
JP2007500673A (ja) 2007-01-18
EP1658046A1 (de) 2006-05-24
GB0317999D0 (en) 2003-09-03
AU2004262873A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
ATE416754T1 (de) Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
NO20030885L (no) Inhibitorer av <alfa>4 styrt celleadhesjon
DE60335560D1 (de) Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE60106229D1 (de) Uv-verstärktes silylierungsverfahren zur erhöhung des ätzwiderstands von dünnen resistschichten
BR0310092A (pt) Combinação de compostos orgânicos
PL373333A1 (pl) Stosowanie przeciwciał skierowanych przeciw TNFalfa i innego leku
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
FI20040668L (fi) Platinaryhmän metalleja sisältävien malmimateriaalien valmistus
EP1609837A4 (de) Reibungsmaterialzusammensetzung und daraus hergestelltes reibungsmaterial
EP1527196A4 (de) Behandlung von asthma und allergien
CO5690533A2 (es) Composicion farmaceutica que comprende micro-particulas de octreotida
EP1620553A4 (de) Insekten-chymotrypsin und inhibitoren davon
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
EP1663255A4 (de) Withanamid und withanolid-zusammensetzungen und anwendungsverfahren dafür
AP1795A (en) Peptide deformylase inhibitors.
EP1624880A4 (de) Annatto-extrakt-zusammensetzungen mit geranyl-geraniolen und anwendungsverfahren
PT1686997E (pt) Inibidores da forma mutante de kit
EP1695956A4 (de) Cyclische carbonsäureverbindung und deren anwendung
ATE536886T1 (de) Stabilisierte feste zusammensetzungen von modifizierter faktor vii
NO20052839L (no) NADH/NADPH-inneholdende sammensetning
EP1547594A4 (de) MITTEL ZUR PRûVENTION ODER BEHANDLUNG VON DEKUBITUS
ATE273985T1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung
MXPA03004148A (es) Recubrimiento durable para reacondicionamiento .

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties